Recent Therapeutic Advancements and Patient Management Recommendations within Metastatic Breast Cancer

This Medical Meeting Reporter will summarize and analyze critical scientific information from the 2014 San Antonio Breast Cancer Symposium (SABCS).

SABCS is a significant professional association of oncologists and strives to promote the highest caliber of patient-centered care. The SABCS Annual Meeting is held each winter and given the considerable number of important presentations, there is a need for clinicians who treat breast cancer to be made aware of these data and understand how the data can be applied to their practice, especially in the case of understanding and applying optimal use of therapies. This CME activity will address that need and provide clinicians with the latest science to support and enhance their overall management of patients with breast cancer.

Target Audience

This activity has been designed to meet the educational needs of oncologists, gynecologists, surgeons, and other healthcare professionals responsible for the diagnosis, treatment, or management of patients with breast cancer.

Learning Objectives

Upon completion of this activity, participants will be able to:

  1. Identify clinical classifications and disease progressive biomarkers in metastatic, and triple negative breast cancer.
  2. Analyze clinical trial data and mechanisms of action of available and developing therapeutics for metastatic breast cancer, as well as risk-benefit considerations in therapeutic selection.
  3. Implement disease monitoring and patient screening strategies to develop personalized treatment plans to optimize patient outcomes in advanced metastatic breast cancer.

Faculty

Eric P. Winer, MD
Director, Breast Oncology Center, Susan F. Smith Center for Women's Cancers
Thompson Chair in Breast Cancer Research
Professor of Medicine, Harvard Medical School
Dana-Farber Cancer Institute
Boston, Massachusetts

Ian E. Krop, MD
Assistant Professor
Department of Medicine, Harvard Medical School
Adult Oncology, Dana-Farber Cancer Institute
Boston, Massachusetts

Nancy U. Lin, MD
Assistant Professor of Medicine
Harvard Medical School Medical Oncologist
Dana-Farber Cancer Institute
Boston, Massachusetts

Disclosure Statements

It is the policy of the Elsevier Office of Continuing Medical Education that all faculty, instructors, and planners disclose real or apparent conflicts of interest relating to the topics of this educational activity.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

Name of Faculty or PresenterRelationship Identified With:
Eric P. Winer, MDGrant/Research Support: Genentech, Inc.; Novartis Pharmaceuticals Corporation
GIan E. Krop, MDGrant/Research Support: Genentech, Inc.; Novartis Pharmaceuticals Corporation
Nancy U. Lin, MDGrant/Research Support: Array BioPharma; Genentech, Inc.; GlaxoSmithKline; Novartis Pharmaceuticals Corporation

Non-faculty: Sandy Breslow; Brynne Hunter; Timothy Hayes, MD, PhD; Kristen Scollon; Emma Gilmartin; Jaimie Kelly; and Bernard Abrams, MD hereby state that they or their spouse/life partner do not have any financial relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.

Financial Support

 

This activity has been supported by an independent educational grant from Celgene Corporation.

Provider Information

Co-provided by the Elsevier Office of Continuing Medical Education and AcademicCME.


Course Open Date: April 27, 2015 | Course Expiration Date: April 26, 2016

CME Credit (Physicians)

The Elsevier Office of Continuing Medical Education is accredited by the Acceditation Council for Continuing Medical Education (ACCME) to provide continuing education for physicians.

The Elsevier Office of Continuing Medical Education designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CME Inquiries/Special Needs

For all CME inquiries or special needs, please contact elsevierCME@elsevier.com.


Disclosure of Unlabeled Use: This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The Elsevier Office of Continuing Medical Education, AcademicCME, and Celgene Corporation do not recommend the use of any agent outside of the labeled indications.

Disclaimer: Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

System Requirements

Privacy Policy

Course summary
Course opens: 
04/27/2015
Course expires: 
04/26/2018
Rating: 
5

Available Credit

Accreditation Period

Course opens: 
04/27/2015
Course expires: 
04/26/2018
Please login or register to take this course.